Well, it's a good thing that CUV's drug has an impeccable safety record over decades of use which makes writing about the history of melanocortin drugs and their safety and trial record kinda.....irrelevant. And here's your very post which I've linked at the end where you cite success rates for drugs from P2 and then P3 trials quoting the FDA no less - might be worth quoting those stats which you hold in high regard again when you warn of a competitor drug that is just starting Phase 2. Which is: 33% of drugs make it through Phase 2 and from there about 30% make it through Phase 3 meaning for a drug at the start of Phase 2, it has a 10% chance of getting through both phases to approval.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)